“…DEFB1 [136], SLC11A1 [137], SPINK1 [138], CCR1 [139], GLUL (glutamate-ammonia ligase) [140], GPR84 [141], SIGLEC5 [142], SIGLEC7 [143], LGR5 [144], CD38 [145], GRB14 [146], PRDX1 [147], SLC19A2 [148], CADM2 [149], TRPM5 [150], COL1A1 [151], CTRB1 [152], UTS2R [153], CRTC1 [154], MUC5B [155], TMPRSS6 [156], SLC5A2 [157] and KCNJ9 [158] expression were shown to play an important role in diabetes mellitus, but these genes might be novel target for MI. MT1A [159], LYVE1 [160], S100A12 [161], GCKR (glucokinase regulator) [162], TLR8 [163], MRC1 [164], AGTR1 [165], P2RY12 [166], MSR1 [167], NQO1 [168], FKBP5 [169], CMTM5 [170], ADH1C [171], APLNR (apelin receptor) [172], SFRP4 [173], CCL3 [174], COL11A2 [175], EGR3 [176] and IL2RB [177] expression have a role in coronary artery disease. EDN2 [178], SNX10 [179] and KCNN1 [180] were played a predominant role in progression of atrial fibrillation.…”